Mayzent

We are now into July and this drug is going nowhere fast!

 

200 bravo points

 

Nice job Jayson

 

We are actually in worse shape than Genzyme and Biogen.

 

Isn’t there some “amazing” drug in your pipeline for MS? Or is that the next Novartis Flop?

 

Pipeline?

Novartis is a house of cards.

 

We are doomed!

 

We are in August- this launch is terribly pathetic. When will the downsizing’s start?

 

get rid of the FRMs , fucking waste of money and oxygen

 

This place is a joke!

 

This drug is a joke!

 

Will we Reorg by the end of the year?

 

we had a neuro team in place selling gilenya, they forced 90% of that team to selling Aimovig, hired 75 more reps....they then split in 2 ..MS and neuroscience....hired the mayzent team ..more reps....then had the BACE inhibitor fail in pipeline and EMA 401 fail in pipeline....Aimovig is getting clubbed like a baby seal by competition BC no payors cover it.....mayzent not launching well... so now they want us to go back to 1 franchise, 1 neuro team after splitting us 18 months ago? Never should have happened in the first place. Revolving door of bodies at the top but nobody seems to know how to right this ship.

 

This place is a hell hole.

 

When the sales team can’t sell for &@$? .......they blame everyone else

 

Not true. It’s amazing we have any writers- because we can sell.

We would sell more if Novartis could get better coverage.

 

Mayzent Is doomed!

 

how about that data at ectrims? Pretty awesome! That being said, Ofat can be a 20 billion dollar drug and we will still make pennies for bonus. The Novartis way.

 

Pretty awesome? vs aubagio - the weakest drug.

 

And Mavenclad is starting to pick up steam. Novartis once again is clueless about how to launch!